Clinical Trials Logo

Filter by:
NCT ID: NCT02027896 Completed - Hip Fractures Clinical Trials

HIP Fracture Accelerated Surgical TreaTment And Care tracK (HIP ATTACK) Trial

HIP ATTACK
Start date: March 14, 2014
Phase: N/A
Study type: Interventional

HIP ATTACK is an international randomized controlled trial of 3000 patients with a hip fracture that requires a surgical intervention. This trial will determine the effect of accelerated medical clearance and accelerated surgery compared to standard care on the 90-day risk of mortality and major perioperative complication (i.e., a composite of mortality, nonfatal myocardial infarction, nonfatal pulmonary embolism, nonfatal pneumonia, nonfatal sepsis, nonfatal stroke, and nonfatal life-threatening and major bleeding).

NCT ID: NCT02006498 Completed - Clinical trials for Non-alcoholic Fatty Liver Disease

Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)

Start date: June 2012
Phase: Phase 2
Study type: Interventional

This is a randomised study to examine whether high dose Sillymarin will be able to help improve fat-induced liver damage in the liver. The study hypothesis is that high dose Sillymarin will be able to reduce steato-hepatitis (fat-related liver inflammation) better than placebo.

NCT ID: NCT02004873 Completed - Clinical trials for Class I or II Indication for Implantation of a Single Chamber Ventricular Pacemaker According to ACC/AHA/HRS 2001 Guidelines and Any National Guidelines

Micra Transcatheter Pacing Study

Start date: November 2013
Phase: N/A
Study type: Interventional

The purpose of this clinical study is to evaluate the safety and efficacy of the Micra Transcatheter Pacing System and to assess long term performance.

NCT ID: NCT02003144 Completed - Clinical trials for Neuromyelitis Optica

An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

Start date: January 12, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.

NCT ID: NCT02001012 Completed - Clinical trials for Uncomplicated Knowlesi Malaria

P. Knowlesi Trial of Artemether-lumefantrine vs Chloroquine

CAN KNOW
Start date: January 2014
Phase: Phase 3
Study type: Interventional

Preliminary studies have supported the background efficacy of local standard anti-malarial medications in the treatment of uncomplicated knowlesi malaria, however there are no current WHO treatment guidelines for this infection. There are both health cost benefits to a more rapidly acting agent, and due to difficulties with microscopic identification there may be more effective treatment for all malaria species if an aligned treatment guideline could be supported. We are currently conducting a separate RCT using a similar protocol evaluating artesunate-mefloquine versus chloroquine for uncomplicated P. knowlesi malaria. However artemether-lumefantrine should also be compared against chloroquine due to the fact it is also a first line anti-malarial recommended in Malaysia, and there are potential differences in efficacy due to the different administration, absorption and half-life of artemether-lumefantrine. The investigators aim to test whether the fixed combination of artesunate-mefloquine is superior to chloroquine in order to define the optimal treatment for both uncomplicated P. knowlesi infection in both adults and children in this region.

NCT ID: NCT01992133 Completed - Clinical trials for Vitamin D Deficiency

Effects of Vitamin D Supplementation on Glucose Metabolism in Women With Former Gestational Diabetes Mellitus

Start date: June 2011
Phase: N/A
Study type: Interventional

Gestational Diabetes Mellitus (GDM) and vitamin D deficiency are related to insulin resistance and impaired beta-cell function, with heightened risk for future development of diabetes. The investigators hypothesize that vitamin D supplementation to women with previous gestational diabetes may improve glucose metabolism.

NCT ID: NCT01990534 Completed - Hodgkin Lymphoma Clinical Trials

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Start date: March 14, 2014
Phase: Phase 4
Study type: Interventional

This phase 4, single-arm, open-label, multicenter study is designed to evaluate the efficacy and safety of brentuximab vedotin as a single agent in adult participants with histologically confirmed CD30+ relapsed or refractory classical Hodgkin Lymphoma who have not received a prior stem cell transplantation (SCT) and are considered to be not suitable for SCT or multiagent chemotherapy at the time of study entry.

NCT ID: NCT01990118 Completed - Clinical trials for End Stage Renal Failure

Gengraf Conversion Study in Stable Renal Allograft Transplant Recipients

Start date: November 2004
Phase: Phase 4
Study type: Interventional

The purpose of this study is to establish the therapeutic equivalence of Gengraf® with the standard treatment Neoral® for a treatment period of 6 months in stable renal allograft transplant recipients with respect to drug levels, dosage, and acute graft rejection and other adverse events.

NCT ID: NCT01989754 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

CANVAS-R
Start date: January 16, 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the effect of canagliflozin compared to placebo on progression of albuminuria in participants with Type 2 Diabetes Mellitus receiving standard care but with inadequate glycemic control and at elevated risk of cardiovascular events.

NCT ID: NCT01988662 Completed - Clinical trials for Neovacular Age-related Macular Degeneration

UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-VEGF Effects in Patients With neovascuLar AMD

UNRAVEL
Start date: April 2014
Phase: Phase 4
Study type: Interventional

This study will assess systemic VEGF level in patients with neovascular Age-related Macular Degeneration following treatment with Ranibizumab or Aflibercept